Abstract
Central nervous system (CNS) malignancies represent one ofthe most devastating forms of cancer. Malignant gliomas, the most commonly occurring primary tumor of the CNS, have a particularly bleak prognosis despite surgery and combined radiation and chemotherapy (1, 2). Immunological approaches to diagnosis and treatment have seemed attractive, but in the past have been frustrated by technological limitations (3, 4). Monoclonal antibody methodology offers major advantages over conventional methods of antiserum production: a practically unlimited source of homogeneous, highly specific reagent which may be prepared using impure or complex antigens. This has led to a new age in neuroimmunology and neuro-oncology, with the potential for better understanding of the basic cell biology of CNS neoplasia, and for improvement in diagnosis, imaging, and therapy.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Green (S.B.), Byar (D.P.), Walker (M.D.), et al.: Comparisons of carmustine, procarbazine, and high dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. Cancer Treat Rep, 67: 121–132 (1983).
Walker (M.D.), Alexander (E.), Hunt (W.E.), MacCarty (C.S.), Mahaley (M.S.), Norrel (H.A.), Owens (G.), Ransahoff (J.), Wilson (C.B.), Gehan (E.A.), Strike (T.A.): Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. J. Neurosurg., 43: 333–343 (1978).
Mahaley (M.S.), Mahaley (J.L.), Day (E.D.): Localization of radioantibodies in human brain tumors II. Radioautography. Cancer Res., 2: 779–793 (1965).
Mahaley (M.S.), Day (E.D.), Bigner (D.D.): Problems inherent to the in vivo localization of anti-brain tumor antibodies. Ann NY Acad. Sci., 159: 451–460 (1969).
Pegram (C.N.), Eng (L.F.), Wikstrand (C.J.), Mccomb (R.D.), Lee (Y.L.), Bigner (D.D.): Monoclonal antibodies reactive with epitopes restricted to glial fibrillary acidic protein of several species. Neurochem. Pathol., 3: 119–138 (1985).
Mclendon (R.E.), Burger (P.C.), Pegram (C.N.), Eng (L.F.), Bigner (D.D.): The immunohistochemical application of three anti-GFAP monoclonal antibodies to formalin-fixed paraffin-embedded normal and neoplastic brain tissues. J. Neuropathol. Exp. Neurol., 45: 692–703 (1986).
Vick (W.W.), Bigner (S.H.), Wikstrand (C.J.), Bullard (D.E.), Kemshead (J.), Coakham (H.G.), Schlom (J.), Johnston (W.W.), Bigner (D.D.): The use of a panel of monoclonal antibodies in the evaluation of cytologic specimens from the central nervous system. In press, Acta Cytol (1986).
Bourdon (M.A.), Wikstrand (C.J.), Furthmayr (H.), Matthews (T.J.), Bigner (D.D.): Human gliomamesenchymal extracellular matrix antigen defined by monoclonal antibody. Cancer Res., 43: 2796–2805 (1983).
Wikstrand (C.J.), Mclendon (R.E.), Bullard (D.E.), Fredman (P.), Svennerholm (L.), Bigner (D.D.): Production and characterization of two human glioma xenograft-localizing monoclonal antibodies (Mabs). Cancer Res., 46: 5933–5940 (1986).
Wikstrand (C.J.), Mclendon (R.E.), Carrel (S.), Kemshead (J.T.), Mach (J.P.), Coakham (H.B.), Tribolet (N. de), Bullard (D.E.), Zalutsky (M.R.), Bigner (D.D.): Comparative localization of glioma reactive-monoclonal antibodies in vivo in an athymic mouse human glioma xenograft model. In press, J. Neuroimmunol. (1986).
Bourdon (M.A.), Coleman (R.E.), Blasberg (R.G.), Groothuis (D.R.), Bigner (D.D.): Monoclonal antibody localization in subcutaneous and intracranial human glioma xenografts: paired label and imaging analysis. Anticancer Res, 4:133–140 (1984).
Bullard (D.E.), Adams (C.J.), Coleman (R.E.), Bigner (D.D.): In vivo imaging of intracranial human glioma xenografts comparing specific with nonspecific radiolabeled monoclonal antibodies. J. Neurosurg., 64: 257–262 (1986).
Allan (P.M.), Garson (J.A.), Harper (E.L.), Asser (U.), Cookham (H.B.), Brownell (B.), Kemshead (J.T.): Biological characterization and clinical application of a monoclonal antibody recognizing an antigen restricted to neuro-ectodermal tissues. Int. J. Cancer 31: 591–598 (1983).
Carrel (S.), Accola (R.S.), Karmeyola (A.L.), Mach (J.P.): Common human melanoma associated antigen (s) detected by monoclonal antibodies. Cancer Res 40: 2523–2528 (1980).
Coakham (H.B.), Garson (J.A.), Allan (P.M.), Harper (E.L.), Brownell (B.), Kemshead (J.T.), Lane (E.B.): Immunohistological diagnosis of central nervous system tumors using a monoclonal antibody panel. J. Clin Path 38: 165–173 (1985).
Davies (A.G.), Richardson (R.B.), Bourne (S.P.), Kemshead (J.T.), Coakham (H.B.): Immunolocalisation of human brain tumours. in Bleehan n (E.D.) Tumours of the Brain (Springer-Verlag, 1986).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1987 Martinus Nijhoff Publishers, Dordrecht
About this chapter
Cite this chapter
Colapinto, E.V. et al. (1987). The Applications of Monoclonal Antibodies in Neuro-Oncology. In: Chatel, M., Darcel, F., Pecker, J. (eds) Brain Oncology Biology, diagnosis and therapy. Developments in Oncology, vol 52. Springer, Dordrecht. https://doi.org/10.1007/978-94-009-3347-7_21
Download citation
DOI: https://doi.org/10.1007/978-94-009-3347-7_21
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-010-8003-3
Online ISBN: 978-94-009-3347-7
eBook Packages: Springer Book Archive